Paeds · genetics-dysmorphology-and-metabolism
Genomic testing, variant interpretation and counselling
Also known as Genomic medicine · Next-generation sequencing in paediatrics · ACMG/AMP variant classification · Secondary findings in genomic sequencing · Pre- and post-test genetic counselling
A fellowship approach to genomic testing in paediatrics: choose the right test from the hierarchy of karyotype, chromosomal microarray, gene panel, exome, and whole-genome sequencing; apply the ACMG/AMP five-tier variant classification framework to interpret results; manage variants of uncertain significance and secondary findings; and deliver pre- and post-test genetic counselling that equips families for diagnosis, uncertainty, and cascade testing — because the diagnostic yield of genome sequencing in rare paediatric disease now reaches 40 to 50 percent.
On this page & tools
Your progress
Saved locally on this device.
Practise this topic
Target exams
Red flags
Life stages
Care settings
Clinical exam formats
Board mappings
The fellowship mark goes to the candidate who thinks in three layers at once. The first layer is the test and its yield: what question is being asked, which test answers it, and what the diagnostic probability is before the sample is sent. The second is the variant and its classification: the ACMG/AMP framework that converts raw sequence data into a probabilistic call, and the distinction between a pathogenic finding that drives management and a VUS that does not. The third is the family: the consent conversation that precedes testing, the disclosure that follows, the cascade testing of relatives, and the re-analysis that keeps the result alive as knowledge grows. [1] [3]
Overview & Definition
Genomic testing in paediatrics encompasses the range of laboratory techniques used to identify genetic variation underlying congenital anomalies, developmental disorders, and inherited diseases. The hierarchy runs from the traditional karyotype, which detects large-scale chromosomal rearrangements visible under a microscope, through chromosomal microarray (CMA), which detects sub-microscopic copy-number variants (CNVs) at far higher resolution, to next-generation sequencing technologies — gene panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) — that read the DNA letter by letter and can identify single-nucleotide variants, small insertions and deletions, and some structural rearrangements. [2] [9]
The clinical application of these technologies depends on a structured variant interpretation process that converts millions of sequence differences into a small number of clinically actionable calls. The American College of Medical Genetics and Genomics and the Association for Molecular Pathology published the consensus standards for this process in 2015, establishing a five-tier classification framework — pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign — that every clinical genomics laboratory now applies. This framework, combined with structured pre- and post-test genetic counselling, defines the modern practice of genomic medicine in paediatrics. [1] [10]
You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References10Show ledgerHide ledger
- [1]Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015.PMID 25741868
- [2]Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet, 2010.PMID 20466091
- [3]Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med, 2013.PMID 23788249
- [4]Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med, 2017.PMID 27854360
- [5]Miller DT, Lee K, Chung WK, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 2021.PMID 34012068
- [6]Smedley D, Smith KR, Martin A, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. N Engl J Med, 2021.PMID 34758253
- [7]Willig LK, Petrikin JE, Smith LD, Saunders CJ, Thiffault I, Miller NA, et al. Whole-genome sequencing for identification of Mendelian disorders in critically ill newborns: a retrospective analysis of diagnostic and clinical trajectories. Lancet Respir Med, 2015.PMID 25937001
- [8]Jansen S, Vissers LELM, de Vries BBA The Genetics of Intellectual Disability. Brain Sci, 2023.PMID 36831774
- [9]Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 2021.PMID 34211152
- [10]Tavtigian SV, Harrison SM, Boucher KM, et al. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat, 2020.PMID 32720330